Cellectar Biosciences (NV40) Price & Analysis
NV40 Stock Chart & Stats
- Day’s Range
- EUR 0.28 - EUR 0.29
- 52-Week Range
- EUR 0.28 - EUR 0.29
- Previous Close
- EUR 0.29
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- EUR 10.16M
- Enterprise Value
- EUR 1.54M
- Total Cash (Recent Filing)
- EUR 33.99M
- Total Debt (Recent Filing)
- EUR 1.53M
- Price to Earnings (P/E)
- ―
- Beta
- -0.13
- Next Earnings
- Mar 11, 2027
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Durable Clinical Efficacy
Strong response rates and durable benefit in late-line patients provide meaningful clinical validation for iopofosine I-131. If sustained in confirmatory testing, these results could support differentiation, regulatory progress, and eventual adoption in an underserved hematologic cancer setting.
Defined Regulatory Pathway
The company has moved beyond exploratory development toward a confirmatory Phase III program and a specified accelerated-approval objective. Breakthrough Designation and an anticipated six-month review could shorten the path from clinical validation to potential commercialization if execution remains on schedule.
Platform And Manufacturing Readiness
A validated phospholipid drug-conjugate platform and established manufacturing infrastructure could support more than one oncology program and facilitate scale-up after approval. Reported ligand stability and available finished-product capacity reduce the need to build these capabilities from scratch.
Bears Say
Pre-commercial Losses
The company remains pre-commercial and has no recurring product revenue to fund operations, while losses continue despite improvement from 2024. Until a therapy is approved and launched, future progress depends on clinical execution and access to external capital rather than internally generated earnings.
Persistent Cash Burn
Negative operating and free cash flow show that the business is not self-funding its development programs. Continued spending on the confirmatory study and pipeline expansion can consume liquidity over the next several quarters, increasing dependence on financing before commercial revenue begins.
Milestone-dependent Financing And Dilution
A substantial portion of the announced financing is conditional on execution and warrant-related criteria, so the full capital plan is not assured. The large warrant package also creates potential dilution, which may reduce the economic benefit to existing shareholders if exercised.
Cellectar Biosciences News
Cellectar’s New Phase 3 WM Trial Puts Iopofosine I 131 on Investors’ Radar
Cellectar Biosciences Inc ($CLRB) announced an update on their ongoing clinical study. Cellectar Biosciences, Inc. (CLRB) has launched a Phase 3 study titled “An Open-Label, Multicenter, Randomized Trial of Iopofosine
NV40 FAQ
What was Cellectar Biosciences’s price range in the past 12 months?
What is Cellectar Biosciences’s market cap?
When is Cellectar Biosciences’s upcoming earnings report date?
How were Cellectar Biosciences’s earnings last quarter?
Is Cellectar Biosciences overvalued?
Does Cellectar Biosciences pay dividends?
What is Cellectar Biosciences’s EPS estimate?
How many shares outstanding does Cellectar Biosciences have?
What happened to Cellectar Biosciences’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Cellectar Biosciences?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Cellectar Biosciences
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- James V. Caruso
- Employees
- 11
- Website
- www.cellectar.com
- Address
- 100 Campus Drive, Florham Park, NJ, 07932, US
Cellectar Biosciences (NV40) Earnings & Revenues
NV40 Earnings Call
Earnings Call SentimentPositive
The call conveyed strong clinical validation for iopofosine (durable responses and high response rates including a near-80% major response in the BTKi-exposed subgroup), clear progress toward a confirmatory Phase III and an intended accelerated approval filing in 1H 2027, plus meaningful balance-sheet reinforcement from an oversubscribed financing. The company is also advancing CLR 125 and expanding its PDC platform with supporting peer-reviewed data and manufacturing readiness. Offsetting these positives are materially higher R&D costs, a wider net loss in dollar terms, timing and operational risks tied to site activation/IRB/radiopharmacy readiness, just-in-time isotope production complexities, actinium-225 supply risk for alpha programs, and potential dilution from issued warrants. Overall, the highlights (clinical data, regulatory path, financing, pipeline expansion and manufacturing preparedness) materially outweigh the operational and financing caveats.
View all DE:NV40 earnings summariesNV40 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 3 | 9 |
| Technical Analysis | 1 | 1 | 3 |
| Moving Averages | 4 | 2 | 6 |